Alnylam Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Alnylam Pharmaceuticals Inc. reported revenue of $3.7B (+65.2% year on year) and net income of $313.7M (+212.8% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Total revenues | $3.7B | $2.2B | $1.8B | $1.0B |
| Cost of goods sold | $677.2M | $306.5M | $268.2M | $140.2M |
| Cost of collaborations and royalties | $4.7M | $16.9M | $42.2M | $28.6M |
| Research and development | $1.3B | $1.1B | $1.0B | $883.0M |
| Selling, general and administrative | $1.2B | $975.5M | $795.6M | $770.7M |
| Total operating costs and expenses | $3.2B | $2.4B | $2.1B | $1.8B |
| Income (loss) from operations | $501.6M | ($176.9M) | ($282.2M) | ($785.1M) |
| Interest expense | ($252.6M) | ($141.9M) | ($121.2M) | ($156.0M) |
| Interest income | $111.5M | $122.0M | $95.6M | — |
| Loss related to convertible debt | ($42.5M) | — | — | — |
| Other income (expense), net | $5.2M | ($180.6M) | ($125.7M) | ($109.4M) |
| Total other expense, net | ($178.4M) | ($200.5M) | ($151.3M) | ($341.9M) |
| Income (loss) before income taxes | $323.2M | ($377.4M) | ($433.5M) | ($1.1B) |
| (Provision for) benefit from income taxes | ($9.4M) | $99.2M | ($6.7M) | ($4.2M) |
| Net income (loss) per common share, basic (in dollars per share) | $2.39 | -$2.18 | -$3.52 | -$9.30 |
| Net income (loss) per common share, diluted (in dollars per share) | $2.33 | -$2.18 | -$3.52 | -$9.30 |
| Weighted average common shares, basic (in shares) | 131.0M | 127.7M | 124.9M | 121.7M |
| Weighted average common shares, diluted (in shares) | 134.7M | 127.7M | 124.9M | 121.7M |
| Net income (loss) | $313.7M | ($278.2M) | ($440.2M) | ($1.1B) |
| Unrealized gains (losses) on marketable securities | $1.8M | ($4.0K) | $11.0M | ($7.8M) |
| Foreign currency translation gains (losses) | $11.6M | — | — | — |
| Defined benefit pension plans, net of tax | $981.0K | ($1.5M) | ($1.7M) | $1.7M |
| Net other comprehensive loss | $14.4M | — | — | — |
| Comprehensive income (loss) | $328.2M | ($289.3M) | ($419.0M) | ($1.1B) |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Total revenues | $1.3B | $1.2B | $1.2B | $773.7M |
| Cost of goods sold | $298.3M | $207.5M | $197.2M | $142.0M |
| Cost of collaborations and royalties | $190.0K | $3.6M | $2.9M | $924.0K |
| Research and development | $413.1M | $364.9M | $358.8M | $323.6M |
| Selling, general and administrative | $347.9M | $322.6M | $322.1M | $323.3M |
| Total operating costs and expenses | $1.1B | $898.5M | $881.0M | $789.9M |
| Income (loss) from operations | $231.4M | $268.6M | $368.0M | ($16.2M) |
| Interest expense | ($82.1M) | ($69.3M) | ($44.4M) | ($40.2M) |
| Interest income | $28.1M | $26.6M | $28.7M | $27.5M |
| Other income (expense), net | $273.0K | ($4.3M) | ($74.2M) | ($6.4M) |
| Total other expense, net | ($53.6M) | ($47.0M) | ($129.0M) | ($19.2M) |
| Income (loss) before income taxes | $177.8M | $221.7M | $239.0M | ($35.4M) |
| Provision for income taxes | ($13.3M) | ($15.7M) | $12.1M | ($30.9M) |
| Net income (loss) per common share - basic (in dollars per share) | $1.23 | $1.55 | $1.91 | -$0.51 |
| Net income (loss) per common share — diluted (in dollars per share) | $1.21 | $1.51 | $1.84 | -$0.51 |
| Weighted-average common shares - basic (in shares) | 133.6M | 132.9M | 131.4M | 130.6M |
| Weighted-average common shares - diluted (in shares) | 138.3M | 138.2M | 137.3M | 130.6M |
| Net income (loss) | $164.5M | $206.0M | $251.1M | ($66.3M) |
| Unrealized (losses) gains on marketable securities | ($3.6M) | ($3.7M) | $1.1M | ($343.0K) |
| Foreign currency translation (losses) gains | ($3.7M) | ($1.2M) | $7.0M | $7.9M |
| Defined benefit pension plans, net of tax | $89.0K | $89.0K | $53.0K | $53.0K |
| Total other comprehensive (loss) income | ($7.2M) | ($4.8M) | $8.2M | $7.6M |
| Comprehensive income (loss) | $157.3M | $201.2M | $259.3M | ($58.7M) |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $1.7B | $966.4M | $812.7M | $866.4M |
| Marketable debt securities | $1.3B | $1.7B | $1.6B | $1.3B |
| Marketable equity securities | $0 | $8.2M | $11.2M | $28.1M |
| Accounts receivable, net | $777.6M | $405.3M | $327.8M | $238.0M |
| Inventory | $82.7M | $78.5M | $89.1M | $129.0M |
| Prepaid expenses and other current assets | $281.9M | $117.0M | $126.4M | $132.9M |
| Total current assets | $4.1B | $3.3B | $3.0B | $2.7B |
| Property, plant and equipment, net | $513.1M | $502.8M | $526.1M | $523.5M |
| Operating lease right-of-use assets | $194.9M | $191.1M | $199.7M | $215.1M |
| Deferred tax assets | $126.0M | $116.9M | — | — |
| Restricted investments | $22.2M | $68.6M | $49.4M | $49.4M |
| Other assets | $59.5M | $65.3M | $72.0M | $66.1M |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B |
| Accounts payable | $115.7M | $88.4M | $55.5M | $98.1M |
| Accrued expenses | $1.1B | $887.5M | $713.0M | $545.5M |
| Operating lease liabilities | $45.5M | $41.9M | $41.5M | $42.0M |
| Deferred revenue | $4.8M | $55.5M | $102.8M | $42.1M |
| Liabilities related to the sale of future royalties and development funding | $220.1M | — | — | — |
| Development derivative liability | $0 | — | — | — |
| Total current liabilities | $1.5B | $1.2B | $967.8M | $767.9M |
| Operating lease liabilities, net of current portion | $225.1M | $229.5M | $243.1M | $261.3M |
| Convertible debt | $1.0B | $1.0B | $1.0B | $1.0B |
| Liabilities related to the sale of future royalties and development funding, net of current portion | $1.5B | — | — | — |
| Development derivative liability, net of current portion | $0 | — | — | — |
| Other liabilities | $7.6M | $398.1M | $308.4M | $212.6M |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B |
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0.00 | $0.00 | — | $0.00 |
| Common stock, $0.01 par value per share, 250,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 132,376 shares issued and outstanding as of December 31, 2025; 129,294 shares issued and outstanding as of December 31, 2024 | $1324000.00 | $1293000.00 | — | $1240000.00 |
| Additional paid-in capital | $7.5B | $7.4B | $6.8B | $6.5B |
| Accumulated other comprehensive loss | ($20.1M) | ($34.5M) | ($23.4M) | ($44.7M) |
| Accumulated deficit | ($6.7B) | ($7.3B) | ($7.0B) | ($6.6B) |
| Total stockholders' equity | $789.2M | $67.1M | ($220.6M) | ($158.2M) |
| Total liabilities and stockholders' equity | $5.0B | $4.2B | $3.8B | $3.5B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.7B | $1.7B | $1.5B | $1.1B |
| Marketable debt securities | $1.6B | $1.3B | $1.2B | $1.7B |
| Accounts receivable, net | $912.7M | $884.0M | $964.8M | $567.1M |
| Inventory | $97.1M | $84.0M | $75.4M | $71.7M |
| Prepaid expenses and other current assets | $302.2M | $242.1M | $188.0M | $147.3M |
| Total current assets | $4.6B | $4.2B | $4.0B | $3.6B |
| Property, plant and equipment, net | $554.1M | $518.3M | $501.8M | $499.8M |
| Operating lease right-of-use assets | $183.4M | $189.3M | $191.4M | $192.4M |
| Deferred tax assets | $113.8M | $117.0M | $98.6M | $104.4M |
| Restricted investments | $22.2M | $22.2M | $51.3M | $68.6M |
| Other assets | $65.1M | $63.6M | $55.8M | $57.2M |
| Total assets | $5.6B | $5.1B | $4.9B | $4.6B |
| Accounts payable | $108.0M | $126.6M | $117.6M | $102.4M |
| Accrued expenses | $1.1B | $946.5M | $1.2B | $919.0M |
| Operating lease liabilities | $45.9M | $45.7M | $44.8M | $46.1M |
| Deferred revenue | $4.0M | $3.2M | $2.5M | $15.1M |
| Liabilities related to the sale of future royalties and development funding | $258.6M | $227.5M | — | — |
| Total current liabilities | $1.5B | $1.3B | $1.6B | $1.3B |
| Operating lease liabilities, net of current portion | $210.5M | $218.0M | $223.4M | $224.4M |
| Convertible debt | $1.0B | $1.0B | $1.0B | $1.0B |
| Liabilities related to the sale of future royalties and development funding, net of current portion | $1.5B | $1.5B | — | — |
| Other liabilities | $9.2M | $7.6M | $9.8M | $10.9M |
| Total liabilities | $4.2B | $4.1B | $4.6B | $4.3B |
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 | $1337000.00 | $1334000.00 | $1318000.00 | $1310000.00 |
| Additional paid-in capital | $7.7B | $7.6B | $7.4B | $7.7B |
| Accumulated other comprehensive loss | ($32.1M) | ($24.9M) | ($21.8M) | ($30.0M) |
| Accumulated deficit | ($6.3B) | ($6.5B) | ($7.2B) | ($7.4B) |
| Total stockholders' equity | $1.4B | $1.1B | $233.9M | $250.6M |
| Total liabilities and stockholders' equity | $5.6B | $5.1B | $4.9B | $4.6B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) | $313.7M | ($278.2M) | ($440.2M) | — |
| Depreciation and amortization | $55.7M | $56.7M | $54.1M | $44.5M |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | $238.4M | — | — | — |
| Stock-based compensation expense | $348.2M | $272.1M | $221.7M | $230.6M |
| Realized and unrealized loss on marketable equity securities | $2.3M | $3.0M | $16.9M | $33.3M |
| Loss related to convertible debt | $42.5M | $0 | $0 | $76.6M |
| Change in fair value of development derivative liability | $0 | $170.8M | $91.0M | $94.7M |
| Deferred income taxes | ($2.2M) | ($106.8M) | — | — |
| Other | ($29.8M) | ($39.0M) | $433.0K | $479.0K |
| Accounts receivable, net | ($360.0M) | ($86.5M) | ($87.9M) | ($45.6M) |
| Inventory | $8.5M | $13.6M | $18.4M | ($34.1M) |
| Prepaid expenses and other assets | ($117.7M) | $3.2M | ($9.0M) | ($38.5M) |
| Accounts payable, accrued expenses and other liabilities | $75.1M | $91.1M | $80.8M | $191.8M |
| Deferred revenue | ($50.6M) | ($235.4M) | $55.0M | ($65.9M) |
| Net cash provided by (used in) operating activities | $524.1M | ($8.3M) | $104.2M | ($541.3M) |
| Purchases of property, plant and equipment | ($58.7M) | ($34.3M) | ($62.2M) | ($72.1M) |
| Purchases of marketable securities | ($1.3B) | ($1.6B) | ($1.8B) | ($2.0B) |
| Sales and maturities of marketable securities | $1.8B | $1.6B | $1.6B | $2.2B |
| Proceeds from maturity of restricted investments | $59.8M | $57.9M | $58.5M | $90.0M |
| Purchases of restricted investments | ($59.8M) | ($77.1M) | ($58.5M) | ($98.5M) |
| Other investing activities | ($2.1M) | ($117.0K) | ($4.4M) | ($4.7M) |
| Net cash provided by (used in) investing activities | $436.3M | ($116.8M) | ($336.4M) | $169.4M |
| Proceeds from issuance of 0.00% Convertible Senior Notes due 2028, net | $645.7M | $0 | $0 | $1.0B |
| Purchases of capped calls related to 0.00% Convertible Senior Notes due 2028 | ($35.3M) | — | — | — |
| Repayment of 1.00% Convertible Senior Notes due 2027 | ($1.2B) | — | — | — |
| Payment of issuance costs for revolving credit agreement | ($2.4M) | — | — | — |
| Proceeds from exercise of stock options and other types of equity, net | 250.0M | 303.0M | 147.5M | 259.4M |
| Proceeds from liabilities related to the sale of future royalties and development funding | $6.0M | — | — | — |
| Repayment of liabilities related to the sale of future royalties and development funding | ($14.3M) | — | — | — |
| (Repayment of) proceeds from development derivative liability, net | $0 | ($8.8M) | — | — |
| Net cash (used in) provided by financing activities | ($305.2M) | $294.2M | $172.1M | $425.8M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $34.9M | ($15.2M) | $6.4M | ($7.4M) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $690.2M | $153.8M | ($53.7M) | $46.4M |
| Cash, cash equivalents and restricted cash, beginning of period | $968.7M | $814.9M | $868.6M | $822.2M |
| Cash, cash equivalents and restricted cash, end of period | $1.7B | $968.7M | $814.9M | $868.6M |
| Cash paid for interest | $218.7M | $67.6M | $32.1M | $45.2M |
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | $21.2M | $9.3M | — | $1.0M |
| Capital expenditures included in accounts payable and accrued expenses | $10.9M | $2.3M | $3.8M | $5.2M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income (loss) | $370.5M | $206.0M | $127.3M | ($123.8M) |
| Depreciation and amortization | $27.5M | $13.6M | $42.2M | $28.3M |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | $145.3M | $66.2M | $112.3M | $71.4M |
| Stock-based compensation expense | $156.8M | $70.2M | $276.6M | $168.4M |
| Realized and unrealized loss on marketable equity securities | $0 | $0 | $2.3M | $2.3M |
| Deferred income taxes | $12.0M | $9.3M | $25.0M | $19.4M |
| Other | $11.3M | $3.0M | ($31.5M) | ($37.9M) |
| Accounts receivable, net | ($142.0M) | ($110.4M) | ($544.2M) | ($144.3M) |
| Inventory | ($3.0M) | ($3.3M) | $22.3M | $17.4M |
| Prepaid expenses and other assets | ($65.7M) | ($6.3M) | ($46.7M) | ($26.0M) |
| Accounts payable, accrued expenses and other liabilities | ($114.4M) | ($176.0M) | $249.9M | $26.4M |
| Deferred revenue | ($831.0K) | ($1.6M) | ($52.9M) | ($40.4M) |
| Net cash provided by operating activities | $397.2M | $70.5M | $360.5M | $35.4M |
| Purchases of property, plant and equipment | ($56.5M) | ($21.8M) | ($35.4M) | ($23.3M) |
| Purchases of marketable securities | ($837.3M) | ($261.6M) | ($1.1B) | ($861.2M) |
| Sales and maturities of marketable securities | $486.0M | $213.2M | $1.6B | $856.9M |
| Proceeds from maturity of restricted and other investments | $66.7M | $48.8M | $59.8M | $58.1M |
| Purchases of restricted and other investments | ($22.0M) | ($4.1M) | ($59.8M) | ($58.1M) |
| Other investing activities | ($25.9M) | — | ($2.1M) | — |
| Net cash used in investing activities | ($389.0M) | ($25.5M) | $473.5M | ($27.6M) |
| Proceeds from exercise of stock options and other types of equity, net | 46.7M | 13.2M | 208.3M | 130.6M |
| Proceeds from liabilities related to the sale of future royalties and development funding | $12.0M | $6.0M | — | — |
| Repayment of liabilities related to the sale of future royalties and development funding | ($6.8M) | ($3.4M) | — | — |
| Other financing activities | ($15.0K) | ($9.0K) | — | — |
| Net cash provided by financing activities | $52.0M | $15.7M | ($350.5M) | $97.8M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | ($9.5M) | ($7.1M) | $40.6M | $41.6M |
| Net increase in cash, cash equivalents and restricted cash | $50.7M | $53.6M | $524.1M | $147.2M |
| Cash, cash equivalents and restricted cash, beginning of period | $1.7B | $1.7B | $968.7M | $968.7M |
| Cash, cash equivalents and restricted cash, end of period | $1.7B | $1.7B | $1.5B | $1.1B |
| Cash paid for interest | $122.3M | $64.2M | $105.4M | $81.5M |
| Cash paid for taxes | $14.7M | $2.4M | $2.4M | $1.1M |
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | $0 | $0 | $12.4M | $8.5M |
| Capital expenditures included in accounts payable and accrued expenses | $24.0M | $9.2M | $9.6M | $4.1M |
Alnylam Pharmaceuticals Inc. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.